Neuroblastoma is one of the most frequent, yet distinctive and challenging childhood tumors. The uniqueness of this tumor depends on its biological markers, which classify neuroblastomas into favorable and unfavorable, with 5-year survival rates ranging from almost 100-30%. In this review, we focus on some biological factors that play major roles in neuroblastoma: MYCN, Trk, and ALK. The MYCN and Trk family genes have been studied for decades and are known to be crucial for the tumorigenesis and progression of neuroblastoma. ALK gene mutations have been recognized recently to be responsible for familial neuroblastomas. Each factor plays an important role in normal neural development, regulating cell proliferation or differentiation by activating several signaling pathways, and interacting with each other. These factors have been studied not only as prognostic factors, but also as targets of neuroblastoma therapy, and some clinical trials are ongoing. We review the basic aspects of MYCN, Trk, and ALK in both neural development and in neuroblastoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00595-019-01790-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A temporal (phospho-)proteomic dataset of neurotrophic receptor tyrosine kinase signalling in neuroblastoma.
Sci Data
October 2024
Systems Biology Ireland, School of Medicine, University College Dublin, Dublin, Ireland.
Article Synopsis
- Neurotrophic receptor tyrosine kinases TrkA, TrkB, and TrkC play different roles in neuroblastoma, a childhood cancer, with TrkA linked to better outcomes and lower disease stages, while TrkB is often found in more aggressive forms associated with MYCN amplification.
- This study used advanced mass spectrometry to analyze proteins and phosphoproteins in neuroblastoma cells, revealing substantial data (4,907 proteins, 16,744 phosphosites) that highlights the distinct signaling of these Trk receptors and their interaction with MYCN status.
- The findings could lead to better understanding and treatment strategies for neuroblastoma by clarifying how different Trk receptors influence the
The RUNX Family Defines Trk Phenotype and Aggressiveness of Human Neuroblastoma through Regulation of p53 and MYCN.
Cells
February 2023
Saga International Carbon Particle Beam Radiation Cancer Therapy Center, Saga HIMAT Foundation, Saga 841-0071, Japan.
The Runt-related transcription factor (RUNX) family, which is essential for the differentiation of cells of neural crest origin, also plays a potential role in neuroblastoma tumorigenesis. Consecutive studies in various tumor types have demonstrated that the RUNX family can play either pro-tumorigenic or anti-tumorigenic roles in a context-dependent manner, including in response to chemotherapeutic agents. However, in primary neuroblastomas, RUNX3 acts as a tumor-suppressor, whereas RUNX1 bifunctionally regulates cell proliferation according to the characterized genetic and epigenetic backgrounds, including MYCN oncogenesis.
View Article and Find Full Text PDFTAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways.
Invest New Drugs
June 2021
Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd, 3 Okubo, Tsukuba, Ibaraki, 300-2611, Japan.
Aurora kinase A, a mitotic kinase that is overexpressed in various cancers, is a promising cancer drug target. Here, we performed preclinical characterization of TAS-119, a novel, orally active, and highly selective inhibitor of Aurora A. TAS-119 showed strong inhibitory effect against Aurora A, with an IC value of 1.
View Article and Find Full Text PDFThe roles played by the MYCN, Trk, and ALK genes in neuroblastoma and neural development.
Surg Today
September 2019
Department of Pediatric Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho Kawaramachi Hirokoji Kamigyo-ku, 602-8566, Kyoto, Japan.
Neuroblastoma is one of the most frequent, yet distinctive and challenging childhood tumors. The uniqueness of this tumor depends on its biological markers, which classify neuroblastomas into favorable and unfavorable, with 5-year survival rates ranging from almost 100-30%. In this review, we focus on some biological factors that play major roles in neuroblastoma: MYCN, Trk, and ALK.
View Article and Find Full Text PDFNeuroblastoma treatment in the post-genomic era.
J Biomed Sci
February 2017
Paediatric Research Institute, Fondazione Città della Speranza, Neuroblastoma Laboratory, Corso Stati Uniti, 4, Padua, 35127, Italy.
Neuroblastoma is an embryonic malignancy of early childhood originating from neural crest cells and showing heterogeneous biological, morphological, genetic and clinical characteristics. The correct stratification of neuroblastoma patients within risk groups (low, intermediate, high and ultra-high) is critical for the adequate treatment of the patients.High-throughput technologies in the Omics disciplines are leading to significant insights into the molecular pathogenesis of neuroblastoma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!